Your Messages Inbox
Your Article Summary
See Latest ArticlesNew Analysis Evaluated Impact of Genetic Variation
on Response to Prasugrel
Daiichi Sankyo, 08/17/09
A new substudy from 1,466 patients from the Phase III TRITON–TIMI 38 clinical trial showed that patients who took prasugrel and had a reduced function of the CYP2C19 gene did not have an increased risk of cardiovascular death, heart attack or stroke compared with those patients who had normal function. The substudy results were published online in Circulation on May 2009.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/09/09
The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
Trials, 12/09/09
Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind, randomised controlled trial
The Lancet - Early Online Publication, 12/09/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Freeze-Thaw Performance and Robustness Assessment of Celsius FFT 6L
BioPharm, 12/09/09
Bivariate Random Effects Meta-Analysis of Diagnostic Studies Using Generalized Linear Mixed Models
Medical Decision Making, 12/09/09
The Impact of Disposables on Project Economics in a New Antibody Plant
BioPharm, 12/09/09
Article Search
Sponsor